ResearcherHarvard UniversityActive in the last 2 years
Alan D. D’Andrea
Matched on ORCID iD 0000-0001-6168-6294; OpenAlex author ID A5044648110. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 4
- A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
- A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
- Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-21-1367↗
- Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Harshabad Singh · 4 shared papers, 2021–2026 · strength 0.56
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Geoffrey Ira Shapiro · 4 shared papers, 2021–2026 · strength 0.56
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Andrew J. Aguirre · 4 shared papers, 2021–2026 · strength 0.56
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Brian Matthew Wolpin · 4 shared papers, 2021–2026 · strength 0.56
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- James M. Cleary · 4 shared papers, 2021–2026 · strength 0.56
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Srivatsan Raghavan · 3 shared papers, 2021–2026 · strength 0.44
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Brandon M. Huffman · 3 shared papers, 2021–2026 · strength 0.44
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Douglas Adam Rubinson · 3 shared papers, 2021–2026 · strength 0.43
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after ea… DOI 10.21037/jgo-21-197↗
- Kimberly J. Perez · 3 shared papers, 2021–2026 · strength 0.43
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Paper Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after ea… DOI 10.21037/jgo-21-197↗
- Leah H. Biller · 2 shared papers, 2023–2026 · strength 0.31
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Kimmie Ng · 2 shared papers, 2023–2026 · strength 0.31
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
- Jonathan Andrew Nowak · 2 shared papers, 2021–2026 · strength 0.31
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Panc… DOI 10.1158/1078-0432.ccr-21-1367↗
- Matthew B.B. Yurgelun · 2 shared papers, 2021–2026 · strength 0.31
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after ea… DOI 10.21037/jgo-21-197↗
- Mary Linton B. Peters · 1 shared paper, 2026 · strength 0.19
- Nadine A. Jackson · 1 shared paper, 2026 · strength 0.19
- Andrea J. Bullock · 1 shared paper, 2026 · strength 0.19
- ANDREA C Enzinger · 1 shared paper, 2026 · strength 0.19
- Thomas Adam Abrams · 1 shared paper, 2023 · strength 0.13
- Stephanie K. Dougan · 1 shared paper, 2021 · strength 0.12
- David P. Ryan · 1 shared paper, 2021 · strength 0.12
- Osama E. Rahma · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.